Adrian Newman-Tancredi
is also co-founder and
Chief Scientific Officer
of
Neurolixis Inc.

 

News

Adrian Newman-Tancredi is co-PI of a research grant that has been awarded by International Rett Syndrome Foundation to Neurolixis Inc. Adrian is acting in his capacity as...Read More
Although dementia has high prevalence among the elderly, few drugs are available to treat the Behavioral and Psychological Symptoms of Dementia (BPSD) that often accompany it. Indeed,...Read More
Adrian Newman-Tancredi is PI of a supplementary research grant that has been awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Neurolixis Inc. Adrian is...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.